Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yun Zhu has a total of 57 co-authors. Here are the top co-authors by number of shared publications:

  • Jie Liu

    Department of Dermatology and Venereology, The Second Affiliated Hospital of Kunming Medical University, Kunming, China

    3 shared publications
  • Shuanglan Xu

    Department of Pulmonary and Critical Care Medicine, The Affiliated Hospital of Yunnan University, Key Laboratory of Respiratory Disease Research of Department of Education of Yunnan Province, 650021 Kunming, Yunnan, China

    3 shared publications
  • Zhaowei Teng

    Central Laboratory, The Second Affiliated Hospital of Kunming Medical University, Kunming, China

    3 shared publications
  • Xiaolan Li

    Department of Dermatology, The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China

    2 shared publications
  • Xiqian Xing

    Department of Pulmonary and Critical Care Medicine, The Affiliated Hospital of Yunnan University, Key Laboratory of Respiratory Disease Research of Department of Education of Yunnan Province, Kunming, Yunnan, China

    2 shared publications
  • Yirong Teng

    Department of Dermatology and Venereology, The Sixth Affiliated Hospital of Kunming Medical University, Yuxi, China

    2 shared publications

Latest Publications

  • Open Access

    Application of computed tomographic angiography and a three-dimensional reconstruction technique for repairing facial skin defects

    by Xiaomin Yang, Yongjing He, Qiyang Wang, Likun Zhu, Lechun Lv, Zhaowei Teng, Haotian Luo, Sheng Lu, Yun Zhu, Jihua Wang

    This study aims to assess the clinical value of computed tomographic angiography (CTA) and three-dimensional reconstruction techniques in the repair of fac


  • Open Access

    Associations between type 1 diabetes and autoimmune skin diseases: Mendelian randomization analysis

    by Jie Liu, Yinde Xu, Yuanju Liu, Yun Zhu, Xiaolan Li


  • Identification of a novel inflammation-related gene signature for predicting inflammatory breast cancer survival

    by Weiyu Bai, Qinggang Hao, Zhimeng Zhang, Bingxing Han, Huilin Xiao, Dong Chang, Yun Zhu, Junling Shen, Jianwei Sun


  • Open Access

    Potential Correlation Between Eczema and Hematological Malignancies Risk: A Systematic Review and Meta-Analysis

    by Zuohui Liang, Jie Liu, Hongxia Jin, Yirong Teng, Shuangyan Xu, Weimin Yan, Yun Zhu

    Background: Eczema characterized by itch, sleeplessness, and adverse effects on quality of life is associated with a risk of hematological malignancies. However, there is a controversy pertaining to whether this association implies a greater or lesser risk of hematological cancers. We aimed to explore the link between eczema and hematological malignancies risk. Methods: We systematically searched PubMed and Embase databases from their inception to February 17, 2022. Two reviewers independently screened articles, extracted data and assessed study quality, respectively. The odds ratios and 95% confidence intervals (CIs) were pooled by using fixed or random-effects models. Results: 29 studies involving 2,521,574 participants examined the contribution of eczema to hematological malignancies. We found that eczema significantly increased the risk of Hodgkin's lymphoma (1.44; 95% CI, 1.07–1.95), myeloma (1.15; 95% CI, 1.04–1.28), and significantly decreased the risk of lymphocytic leukemia (0.91; 95% CI, 0.84–0.99); however, it is not significantly associated with Non-Hodgkin's lymphoma, and myelocytic leukemia. Conclusion: Eczema has been shown to be associated with the risk of hematological cancer, this association still needs to be verified in large randomized controlled trials. Systematic Review Registration: https://inplasy.com/, INPLASY202260097.


  • Open Access

    Efficacy and Safety of Remdesivir for COVID-19 Treatment: An Analysis of Randomized, Double-Blind, Placebo-Controlled Trials

    by Yun Zhu, Zhaowei Teng, Lirong Yang, Shuanglan Xu, Jie Liu, Yironog Teng, Qinggang Hao, Dake Zhao, Xiaolan Li, Sheng Lu, et al.

    BACKGROUND: Remdesivir, an inhibitor of viral RNA-dependent RNA polymerases, has been identified as a candidate for COVID-19 treatment. However, the therapeutic effect of remdesivir is controversial. METHODS: We searched PubMed, Embase, and the Cochrane Central Register of Controlled Trials, from inception to June 11, 2020 for randomized controlled trials on the clinical efficacy of remdesivir. The main outcomes were discharge rate, mortality, and adverse events. This study is registered at INPLASY (INPLASY202060046). RESULTS: Data of 1075 subjects showed that remdesivir significantly increased the discharge rate of patients with COVID-19 compared with the placebo (50.4% vs. 45.29%; relative risk [RR] 1.19 [95% confidence interval [CI], 1.05–1.34], I 2 = 0.0%, P = 0.754). It also significantly decreased mortality (8.18% vs. 12.70%; RR 0.64 [95% CI, 0.44–0.92], I 2 = 45.7%, P = 0.175) compared to the placebo. Data of 1296 subjects showed that remdesivir significantly decreased the occurrence of serious adverse events (RR 0.77 [95% CI, 0.63–0.94], I 2 = 0.0%, P = 0.716). CONCLUSION: Remdesivir is efficacious and safe for the treatment of COVID-19. TRIAL REGISTRATION NUMBER: This study is registered at the International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY202060046).


  • The Analysis for Anemia Increasing Fracture Risk

    by Yirong Teng, Zhaowei Teng, Shuanglan Xu, Xiguang Zhang, Jie Liu, Qiaoning Yue, Yun Zhu, Yong Zeng

    Background: Fractures are a major public health problem for elderly people throughout the world. Anemia is also a common, important health problem among elderly populations. The aim of this article was to estimate the association between anemia and fracture incidence via a systematic review and meta-analysis. Material/Methods: The participant, intervention, observation, and study design (PICOS) reporting guidelines were followed, and databases were searched from their inception to May 2020 to identify relevant studies. When heterogeneity was significant, and a random-effects model was used. Subgroup analysis was conducted to explore the source of heterogeneity based on sex, study design, and region. Result: We found that anemia significantly increased fracture risk [relative risk (RR)=1.26, 95% confidence interval (CI)=1.14-1.39, P<0.001], specifically, hip fracture (RR=1.44, 95% CI=1.29-1.61), spine fracture (RR=1.15, 95% CI=1.08-1.23), and nonspine fracture (RR=1.42, 95% CI=1.33-1.52). Males with anemia had a 1.51-fold higher fracture risk, females had a 1.09-fold higher fracture risk. And the association was stronger in Asian (RR=1.22, 95% CI=1.07-1.40), but not in American and European study populations. Conclusions: In conclusion, a significantly increased fracture risk was observed, and anemia can be a predictor of fracture risk.


  • Open Access

    Label-free Quantitative Analysis of Protein Expression Alterations in miR-26a-Knockout HeLa Cells using SWATH-MS Technology

    by Hexiao Shen, Li Li, Zhaowei Teng, Tianqing Meng, Xiangbin Kong, Yan Hu, Yun Zhu, Lixin Ma

    MicroRNAs (miRNAs) bind to the 3ʹ-untranslated region of target mRNAs in a sequence-specific manner and subsequently repress gene translation. Human miR-26a has been studied extensively, but the target transcripts are far from complete. We first employed the CRISPR-Cas9 system to generate an miR-26a-knockout line in human cervical cancer HeLa cells. The miR26a-knockout line showed increased cell growth and altered proliferation. Proteomics technology of sequential window acquisition of all theoretical mass spectra (SWATH-MS) was utilized to compare the protein abundance between the wild-type and the knockout lines, with an attempt to identify transcripts whose translation was influenced by miR-26a. Functional classification of the proteins with significant changes revealed their function in stress response, proliferation, localization, development, signaling, etc. Several proteins in the cell cycle/proliferation signaling pathway were chosen to be validated by western blot and parallel reaction monitoring (PRM). The satisfactory consistency among the three approaches indicated the reliability of the SWATH-MS quantification. Among the computationally predicted targets, a subset of the targets was directly regulated by miR-26a, as demonstrated by luciferase assays and Western blotting. This study creates an inventory of miR-26a-targeted transcripts in HeLa cells and provides fundamental knowledge to further explore the functions of miR-26a in human cancer.


  • Open Access

    Serum cardiac troponin elevation predicts mortality in patients with pulmonary hypertension: A meta‐analysis of eight cohort studies

    by Shuang‐Lan Xu, Jiao Yang, Chun‐Fang Zhang, Shuang‐Yan Xu, Fang‐Yun Zhao, Li‐Qiong Liu, Chun‐Lin Xie, Xi‐Qian Xing, Yun Zhu

    Objective: To determine the association of serum cardiac troponin (cTn) with the mortality of pulmonary hypertension (PH) patients via a meta‐analysis.Date Source: We searched PubMed and EMBASE from inception to October 25, 2017.Study Selection: The reference lists of the retrieved articles were also consulted. The Q test and I2 test were used for to assess heterogeneity. The relationship between cTn elevation and mortality was analysed. Studies were stratified according to type of troponin (cTnT vs cTnI), region (Europe vs America) and follow‐up length (≤3 years vs >3 years).Results: Eight studies with 739 patients were included in the meta‐analysis. Cardiac troponin elevation ranged from 14.3% to 94.5%. Overall, 48.8% (39/80) of patients with elevated cTn died compared to 18.6% (45/242) of patients with normal cTn levels. These findings showed cTn elevation was significantly related to an increased mortality risk in PH patients [hazard ratio (HR) = 3.05, 95% confidence interval (95% CI) = 2.16‐4.32, I2 = 24.9%]. cTnI was better at predicting mortality than cTnT (HR = 3.37, 95%CI = 2.05‐5.55 vs HR = 2.80, 95%CI = 1.97‐3.98, respectively). American populations had increased mortality compared to European populations (HR = 4.23, 95%CI = 2.29‐7.80 vs HR = 2.70, 95% CI = 1.95‐3.74, respectively). This finding was independent of the follow‐up length of the studies (≤3 years: HR = 2.36, 95%CI = 1.65‐3.38; >3 years: HR = 4.55, 95%CI = 2.80‐7.39).Conclusions: Although different studies detected the expression cTnT or cTnI by various methods, the mortality in the cTn‐positive group was higher than that in the cTn‐negative group. Serum cTn elevation emerged as an independent predictor of increased risk of mortality in PH patients.


  • Open Access

    Lymphatic vessel density as a prognostic indicator in Asian NSCLC patients: a meta-analysis

    by Shuanglan Xu, Jiao Yang, Shuangyan Xu, Yun Zhu, Chunfang Zhang, Liqiong Liu, Hao Liu, Yunlong Dong, Zhaowei Teng, Xiqian Xing

    To determine the association of lymphatic vessel density (LVD) with the prognosis of Asian non-small cell lung cancer (NSCLC) patients via a meta-analysis. Eligible studies were selected by searching PubMed and EMBASE from inception to July 25, 2017. The reference lists of the retrieved articles were also consulted. The information was independently screened by two authors. When heterogeneity was significant, a random-effects model was used to determine overall pooled risk estimates. A total of 15 studies with 1075 patients were finally included in the meta-analysis. LVD was positively associated with the prognosis of NSCLC in the overall analysis (hazard ratio (HR) 1.14, 95% confidence interval (95% CI): 1.02–1.27, p = 0.000, I2 = 73.2%). Subgroup analyses were performed on 5 VEGFR-3 groups (p = 0.709, I2 = 0.0%), 3 LYVE-1 groups (p = 0.01, I2 = 86.4%), 5 D2–40 groups (p = 0.019, I2 = 66.2%), and 2 podoplanin groups (p = 0.094, I2 = 64.5%). Sensitivity analysis indicated robust results. There was no publication bias. LVD is an indicator of poor prognosis in Asian NSCLC patients.